Home » Healthcare » Pharmaceuticals » Bacterial Vaginosis Drugs Market

Bacterial Vaginosis Drugs Market By Type (Rx, OTC) By Application (Hospital, Pharmacy, Others) – Growth, Future Prospects & Competitive Analysis, 2016 – 2028

Published: | Report ID: 2103 | Report Format : PDF

Market Insights

According to the Centers for Disease Control and Prevention, the prevalence of bacterial vaginosis is 18.8 percent among celibate women, 25 percent among pregnant women, and 31.7 percent among women who have never been pregnant. The risk factors associated with the disease etiology of bacterial vaginosis are pelvic inflammatory disease, preterm delivery of infants, urinary tract infection, and sexually transmitted diseases (STD). The products in the pipeline in phase 3 for the treatment of bacterial vaginosis are Metronidazole oral tablets, 500 mg; 1% SPL7013 Gel; GDC-229; Clindamycin, 100 mg; Ketoconazole, 400 mg; and the association of metronidazole, nystatin, and dexamethasone.

Design Element 2

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample
CTA Design Element 3

Oral routes comprise Metronidazole, Tinidazole, Clindamycin, and Secnidazole. Metronidazole, clindamycin, and normal pH restoration gels are used topically. Canesbalance and VivaGel® are two sub-categories of normal pH restoration gels. Recent trends prevailing in the bacterial vaginosis drug market are understood by the inclusion of market size and forecast in the scope of the report.

To understand the country’s cross-sectional market of bacterial vaginosis drugs, a market estimate and forecast for the period 2015-2025 have been reported for the major countries included in the regional segments.

The competitive landscape and attractive investment proposition give a clear idea of the first-line treatment drugs employed for the treatment of bacterial vaginosis and the product pipelines of key manufacturers engaged in the bacterial vaginosis treatment industry. A collaborative partnership between the key players to promote recently approved drugs is mentioned in the company profiles considered for the bacterial vaginosis drug market. The major players in the global bacterial vaginosis drugs market are Sanofi Aventis, Inc., Bayer AG, Mylan N.V., Novartis AG, Pfizer, Inc., Perrigo Company Plc, Sun Pharmaceutical Industries Ltd., Abbott Laboratories, Inc., Starpharma Holdings Limited, and Symbiomix Therapeutics.

Based on the route of administration, the bacterial vaginosis drugs market is categorized into:

Oral Route

  • Metronidazole
  • Tinidazole
  • Clindamycin
  • Secnidazole

Topical Route

  • Metronidazole
  • Clindamycin

Normal pH Restoration Gels

  • VivaGel®

Canesbalance

Bacterial vaginosis is the most common type of vaginal infection caused by a pH imbalance in the vaginal environment, which is triggered by an imbalance between the good microflora of Lactobacillus species and the bad microflora of Gardnerella vaginalis. The clinical manifestation of bacterial vaginosis is asymptomatic in nature, with the symptoms recurring after a few days of earlier treatment with antibiotics. The treatment regimen is designed with drug formulations, either oral or topical, that is efficient in eliminating the colonization of Gardnerella vaginalis. Currently, antibiotics are the preferred treatment regimen for bacterial vaginitis, employing drugs such as metronidazole, clindamycin, and tinidazole.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Broad-spectrum antimicrobial activity, e.g., secnidazole (Solosec), and immediate symptomatic relief make antibiotic treatment the largest revenue generator. Metronidazole is considered more beneficial than clindamycin for the treatment of bacterial vaginosis as it is safe during pregnancy and does not eliminate the colonization of the good bacteria Lactobacillus species. Normal pH restoration gels, e.g., Canesbalance (Bayer AG) and VivaGel® (Starpharma Holdings), will have impressive growth in the near future as they address the key problem of microflora imbalance in the vaginal environment and have relatively few side effects in comparison to antibiotics. The prominent players in the bacterial vaginosis drugs market are Abbott Laboratories, Inc., Bayer AG, Mylan N.V., Novartis AG, Pfizer, Inc., Perrigo Company Plc, Sun Pharmaceutical Industries Ltd., Sanofi Aventis, Starpharma Holdings Limited, and Symbiomix Therapeutics.

For the purpose of this study, the global bacterial vaginosis drugs market is categorized into the following regional and country-specific markets:

  • North America
    • United States
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • rest of Latin America
  • Middle East and Africa
    • GCC
    • Rest of the Middle East and Africa

The Centers for Disease Control and Prevention’s 2015 statistics have reported the prevalence of bacterial vaginosis in the North American female population to be around 84 percent with no symptoms. Because of the rising prevalence in African American and Hispanic women, an effective dosage regimen that provides immediate relief is required. The domicile of key pharmaceutical industries engaged in the production and sale of antibiotics contributes to the dominance of North America in the bacterial vaginosis drug market. The European market is driven by the rising prevalence of bacterial vaginosis due to an increase in the lifetime number of sexual partners.

The recent influx of North African refugees with a history of bacterial vaginosis has increased the treatment burden on the European healthcare segment. Asia Pacific will enjoy superlative growth in the bacterial vaginosis drug market due to the huge revenue generated by the generic antibiotic drug market. Poor socioeconomic conditions and a lack of awareness regarding personal hygiene also contribute to the growth of the Asia Pacific bacterial vaginosis drug market. Increasing disposable income and health awareness campaigns regarding self-hygiene by healthcare agencies such as the World Health Organization and Red Cross will proliferate the bacterial vaginosis drug market in Latin America, the Middle East, and Africa.

1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Primary Research
1.3.3. Phase III – Expert Panel Review
1.3.4. Approach Adopted
1.3.4.1. Top-Down Approach
1.3.4.2. Bottom-Up Approach
1.3.5. Assumptions
1.4. Market Segmentation

2. Executive Summary
2.1. Market Snapshot: Global Bacterial Vaginosis Drug Market
2.2. Global Bacterial Vaginosis Drug Market, By Type
2.3. Global Bacterial Vaginosis Drug Market, By Application
2.4. Global Bacterial Vaginosis Drug Market, By Region

3. Market Dynamics & Factors Analysis
3.1. Introduction
3.1.1. Global Bacterial Vaginosis Drug Market Value, 2016-2028, (US$ Bn)
3.2. Market Dynamics
3.2.1. Key Growth Trends
3.2.2. Market Drivers
3.2.3. Market Restraints
3.2.4. Market Opportunities
3.2.5. Major Industry Challenges
3.3. Attractive Investment Proposition,2021
3.3.1. Type
3.3.2. Application
3.3.3. Geography

4. Premium Insights
4.1. STAR (Situation, Task, Action, Results) Analysis
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers/Consumers
4.2.3. Bargaining Power of Suppliers
4.2.4. Threat of Substitute Types
4.2.5. Intensity of Competitive Rivalry
4.3. Value Chain Analysis
4.4. Technology Analysis
4.5. Marketing Strategy Analysis
4.5.1. Direct Marketing
4.5.2. Indirect Marketing
4.5.3. Marketing Channel Development Trend

5. Market Positioning of Key Players, 2021
5.1. Company market share of key players, 2021
5.2. Competitive Benchmarking
5.3. Market Positioning of Key Vendors
5.4. Geographical Presence Analysis
5.5. Major Strategies Adopted by Key Players
5.5.1. Key Strategies Analysis
5.5.2. Mergers and Acquisitions
5.5.3. Partnerships
5.5.4. Product Launch
5.5.5. Geographical Expansion
5.5.6. Others

6. COVID 19 Impact Analysis
6.1. Global Bacterial Vaginosis Drug Market Pre Vs Post COVID 19, 2019 – 2028
6.2. Impact on Import & Export
6.3. Impact on Demand & Supply

7. Global Bacterial Vaginosis Drug Market
7.1. Global Bacterial Vaginosis Drug Market, by Type, 2016-2028(US$ Bn)
7.1.1. Overview
7.1.2. Global Bacterial Vaginosis Drug Market, By Type, 2021 vs 2028 (in%)
7.1.3. Global Bacterial Vaginosis Drug Market, By Rx, 2016-2028 (US$ Bn)
7.1.4. Global Bacterial Vaginosis Drug Market, By OTC, 2016-2028 (US$ Bn)
7.2. Global Bacterial Vaginosis Drug Market, by Application, 2016-2028(US$ Bn)
7.2.1. Overview
7.2.2. Global Bacterial Vaginosis Drug Market, By Application, 2021 vs 2028 (in%)
7.2.3. Global Bacterial Vaginosis Drug Market, By Hospital, 2016-2028 (US$ Bn)
7.2.4. Global Bacterial Vaginosis Drug Market, By Pharmacy, 2016-2028 (US$ Bn)
7.2.5. Global Bacterial Vaginosis Drug Market, By Other, 2016-2028 (US$ Bn)

8. North America Bacterial Vaginosis Drug Market Analysis
8.1. North America Bacterial Vaginosis Drug Market, by Type, 2016-2028(US$ Bn)
8.1.1. Overview
8.1.2. SRC Analysis
8.2. North America Bacterial Vaginosis Drug Market, by Application, 2016-2028(US$ Bn)
8.2.1. Overview
8.2.2. SRC Analysis
8.3. North America Bacterial Vaginosis Drug Market, by Country, 2016-2028 (US$ Bn)
8.3.1. U.S.
8.3.1.1. U.S. Bacterial Vaginosis Drug Market Estimates and Forecast, 2016-2028 (US$ Bn)
8.3.1.2. U.S. Bacterial Vaginosis Drug, By Type, 2016-2028 (US$ Bn)
8.3.1.3. U.S. Bacterial Vaginosis Drug, By Application, 2016-2028 (US$ Bn)
8.3.2. Canada
8.3.2.1. Canada Bacterial Vaginosis Drug Market Estimates and Forecast, 2016-2028 (US$ Bn)
8.3.2.2. Canada Bacterial Vaginosis Drug, By Type, 2016-2028 (US$ Bn)
8.3.2.3. Canada Bacterial Vaginosis Drug, By Application, 2016-2028 (US$ Bn)

9. Europe Bacterial Vaginosis Drug Market Analysis
9.1. Europe Bacterial Vaginosis Drug Market, by Type, 2016-2028(US$ Bn)
9.1.1. Overview
9.1.2. SRC Analysis
9.2. Europe Bacterial Vaginosis Drug Market, by Application, 2016-2028(US$ Bn)
9.2.1. Overview
9.2.2. SRC Analysis
9.3. Europe Bacterial Vaginosis Drug Market, by Country, 2016-2028 (US$ Bn)
9.3.1. Germany
9.3.1.1. Germany Bacterial Vaginosis Drug Market Estimates and Forecast, 2016-2028 (US$ Bn)
9.3.1.2. Germany Bacterial Vaginosis Drug, By Type, 2016-2028 (US$ Bn)
9.3.1.3. Germany Bacterial Vaginosis Drug, By Application, 2016-2028 (US$ Bn)
9.3.2. France
9.3.2.1. France Bacterial Vaginosis Drug Market Estimates and Forecast, 2016-2028 (US$ Bn)
9.3.2.2. France Bacterial Vaginosis Drug, By Type, 2016-2028 (US$ Bn)
9.3.2.3. France Bacterial Vaginosis Drug, By Application, 2016-2028 (US$ Bn)
9.3.3. UK
9.3.3.1. UK Bacterial Vaginosis Drug Market Estimates and Forecast, 2016-2028 (US$ Bn)
9.3.3.2. UK Bacterial Vaginosis Drug, By Type, 2016-2028 (US$ Bn)
9.3.3.3. UK Bacterial Vaginosis Drug, By Application, 2016-2028 (US$ Bn)
9.3.4. Italy
9.3.4.1. Italy Bacterial Vaginosis Drug Market Estimates and Forecast, 2016-2028 (US$ Bn)
9.3.4.2. Italy Bacterial Vaginosis Drug, By Type, 2016-2028 (US$ Bn)
9.3.4.3. Italy Bacterial Vaginosis Drug, By Application, 2016-2028 (US$ Bn)
9.3.5. Spain
9.3.5.1. Spain Bacterial Vaginosis Drug Market Estimates and Forecast, 2016-2028 (US$ Bn)
9.3.5.2. Spain Bacterial Vaginosis Drug, By Type, 2016-2028 (US$ Bn)
9.3.5.3. Spain Bacterial Vaginosis Drug, By Application, 2016-2028 (US$ Bn)
9.3.6. Rest of Europe
9.3.6.1. Rest of Europe Bacterial Vaginosis Drug Market Estimates and Forecast, 2016-2028 (US$ Bn)
9.3.6.2. Rest of Europe Bacterial Vaginosis Drug, By Type, 2016-2028 (US$ Bn)
9.3.6.3. Rest of Europe Bacterial Vaginosis Drug, By Application, 2016-2028 (US$ Bn)

10. Asia Pacific Bacterial Vaginosis Drug Market Analysis
10.1. Asia Pacific Bacterial Vaginosis Drug Market, by Type, 2016-2028(US$ Bn)
10.1.1. Overview
10.1.2. SRC Analysis
10.2. Asia Pacific Bacterial Vaginosis Drug Market, by Application, 2016-2028(US$ Bn)
10.2.1. Overview
10.2.2. SRC Analysis
10.3. Asia Pacific Bacterial Vaginosis Drug Market, by Country, 2016-2028 (US$ Bn)
10.3.1. China
10.3.1.1. China Bacterial Vaginosis Drug Market Estimates and Forecast, 2016-2028 (US$ Bn)
10.3.1.2. China Bacterial Vaginosis Drug, By Type, 2016-2028 (US$ Bn)
10.3.1.3. China Bacterial Vaginosis Drug, By Application, 2016-2028 (US$ Bn)
10.3.2. Japan
10.3.2.1. Japan Bacterial Vaginosis Drug Market Estimates and Forecast, 2016-2028 (US$ Bn)
10.3.2.2. Japan Bacterial Vaginosis Drug, By Type, 2016-2028 (US$ Bn)
10.3.2.3. Japan Bacterial Vaginosis Drug, By Application, 2016-2028 (US$ Bn)
10.3.3. India
10.3.3.1. India Bacterial Vaginosis Drug Market Estimates and Forecast, 2016-2028 (US$ Bn)
10.3.3.2. India Bacterial Vaginosis Drug, By Type, 2016-2028 (US$ Bn)
10.3.3.3. India Bacterial Vaginosis Drug, By Application, 2016-2028 (US$ Bn)
10.3.4. South Korea
10.3.4.1. South Korea Bacterial Vaginosis Drug Market Estimates and Forecast, 2016-2028 (US$ Bn)
10.3.4.2. South Korea Bacterial Vaginosis Drug, By Type, 2016-2028 (US$ Bn)
10.3.4.3. South Korea Bacterial Vaginosis Drug, By Application, 2016-2028 (US$ Bn)
10.3.5. South-East Asia
10.3.5.1. South-East Asia Bacterial Vaginosis Drug Market Estimates and Forecast, 2016-2028 (US$ Bn)
10.3.5.2. South-East Asia Bacterial Vaginosis Drug, By Type, 2016-2028 (US$ Bn)
10.3.5.3. South-East Asia Bacterial Vaginosis Drug, By Application, 2016-2028 (US$ Bn)
10.3.6. Rest of Asia Pacific
10.3.6.1. Rest of Asia Pacific Bacterial Vaginosis Drug Market Estimates and Forecast, 2016-2028 (US$ Bn)
10.3.6.2. Rest of Asia Pacific Bacterial Vaginosis Drug, By Type, 2016-2028 (US$ Bn)
10.3.6.3. Rest of Asia Pacific Bacterial Vaginosis Drug, By Application, 2016-2028 (US$ Bn)

11. Latin America Bacterial Vaginosis Drug Market Analysis
11.1. Latin America Bacterial Vaginosis Drug Market, by Type, 2016-2028(US$ Bn)
11.1.1. Overview
11.1.2. SRC Analysis
11.2. Latin America Bacterial Vaginosis Drug Market, by Application, 2016-2028(US$ Bn)
11.2.1. Overview
11.2.2. SRC Analysis
11.3. Latin America Bacterial Vaginosis Drug Market, by Country, 2016-2028 (US$ Bn)
11.3.1. Brazil
11.3.1.1. Brazil Bacterial Vaginosis Drug Market Estimates and Forecast, 2016-2028 (US$ Bn)
11.3.1.2. Brazil Bacterial Vaginosis Drug, By Type, 2016-2028 (US$ Bn)
11.3.1.3. Brazil Bacterial Vaginosis Drug, By Application, 2016-2028 (US$ Bn)
11.3.2. Mexico
11.3.2.1. Mexico Bacterial Vaginosis Drug Market Estimates and Forecast, 2016-2028 (US$ Bn)
11.3.2.2. Mexico Bacterial Vaginosis Drug, By Type, 2016-2028 (US$ Bn)
11.3.2.3. Mexico Bacterial Vaginosis Drug, By Application, 2016-2028 (US$ Bn)
11.3.3. Rest of Latin America
11.3.3.1. Rest of Latin America Bacterial Vaginosis Drug Market Estimates and Forecast, 2016-2028 (US$ Bn)
11.3.3.2. Rest of Latin America Bacterial Vaginosis Drug, By Type, 2016-2028 (US$ Bn)
11.3.3.3. Rest of Latin America Bacterial Vaginosis Drug, By Application, 2016-2028 (US$ Bn)

12. Middle East and Africa Bacterial Vaginosis Drug Market Analysis
12.1. Middle East and Africa Bacterial Vaginosis Drug Market, by Type, 2016-2028(US$ Bn)
12.1.1. Overview
12.1.2. SRC Analysis
12.2. Middle East and Africa Bacterial Vaginosis Drug Market, by Application, 2016-2028(US$ Bn)
12.2.1. Overview
12.2.2. SRC Analysis
12.3. Middle East and Africa Bacterial Vaginosis Drug Market, by Country, 2016-2028 (US$ Bn)
12.3.1. GCC Countries
12.3.1.1. GCC Countries Bacterial Vaginosis Drug Market Estimates and Forecast, 2016-2028 (US$ Bn)
12.3.1.2. GCC Countries Bacterial Vaginosis Drug, By Type, 2016-2028 (US$ Bn)
12.3.1.3. GCC Countries Bacterial Vaginosis Drug, By Application, 2016-2028 (US$ Bn)
12.3.2. South Africa
12.3.2.1. South Africa Bacterial Vaginosis Drug Market Estimates and Forecast, 2016-2028 (US$ Bn)
12.3.2.2. South Africa Bacterial Vaginosis Drug, By Type, 2016-2028 (US$ Bn)
12.3.2.3. South Africa Bacterial Vaginosis Drug, By Application, 2016-2028 (US$ Bn)
12.3.3. Rest of Middle East and Africa
12.3.3.1. Rest of Middle East and Africa Bacterial Vaginosis Drug Market Estimates and Forecast, 2016-2028 (US$ Bn)
12.3.3.2. Rest of Middle East and Africa Bacterial Vaginosis Drug, By Type, 2016-2028 (US$ Bn)
12.3.3.3. Rest of Middle East and Africa Bacterial Vaginosis Drug, By Application, 2016-2028 (US$ Bn)

13. Company Profiles
13.1. Bayer AG
13.1.1. Company Overview
13.1.2. Products/Services Portfolio
13.1.3. Geographical Presence
13.1.4. Financial Summary
13.1.4.1. Market Revenue and Net Profit (2019-2021)
13.1.4.2. Business Segment Revenue Analysis
13.1.4.3. Geographical Revenue Analysis
13.2. Pfizer
13.3. Sanofi
13.4. Piramal
13.5. Abbott
13.6. Galderma
13.7. Mission
13.8. Alkem
13.9. Xiuzheng
13.10. Teva
13.11. Others

 

List of Figures

FIG. 1 Global Bacterial Vaginosis Drug Market: Research Methodology
FIG. 2 Market Size Estimation – Top Down & Bottom up Approach
FIG. 3 Global Bacterial Vaginosis Drug Market Segmentation
FIG. 4 Global Bacterial Vaginosis Drug Market, by Type, 2021 (US$ Bn)
FIG. 5 Global Bacterial Vaginosis Drug Market, by Application, 2021 (US$ Bn)
FIG. 6 Global Bacterial Vaginosis Drug Market, by Geography, 2021 (US$ Bn)
FIG. 7 Attractive Investment Proposition, by Type, 2021
FIG. 8 Attractive Investment Proposition, by Application, 2021
FIG. 9 Attractive Investment Proposition, by Geography, 2021
FIG. 10 Global Market Share Analysis of Key Bacterial Vaginosis Drug Market Manufacturers, 2021
FIG. 11 Global Market Positioning of Key Bacterial Vaginosis Drug Market Manufacturers, 2021
FIG. 12 Global Bacterial Vaginosis Drug Market Value Contribution, By Type, 2021 & 2028 (Value %)
FIG. 13 Global Bacterial Vaginosis Drug Market, by Rx, Value, 2016-2028 (US$ Bn)
FIG. 14 Global Bacterial Vaginosis Drug Market, by OTC, Value, 2016-2028 (US$ Bn)
FIG. 15 Global Bacterial Vaginosis Drug Market Value Contribution, By Application, 2021 & 2028 (Value %)
FIG. 16 Global Bacterial Vaginosis Drug Market, by Hospital, Value, 2016-2028 (US$ Bn)
FIG. 17 Global Bacterial Vaginosis Drug Market, by Pharmacy, Value, 2016-2028 (US$ Bn)
FIG. 18 Global Bacterial Vaginosis Drug Market, by Others, Value, 2016-2028 (US$ Bn)
FIG. 19 U.S. Bacterial Vaginosis Drug Market, 2016-2028 (US$ Bn)
FIG. 20 Canada Bacterial Vaginosis Drug Market, 2016-2028 (US$ Bn)
FIG. 21 Germany Bacterial Vaginosis Drug Market, 2016-2028 (US$ Bn)
FIG. 22 France Bacterial Vaginosis Drug Market, 2016-2028 (US$ Bn)
FIG. 23 U.K. Bacterial Vaginosis Drug Market, 2016-2028 (US$ Bn)
FIG. 24 Italy Bacterial Vaginosis Drug Market, 2016-2028 (US$ Bn)
FIG. 25 Spain Bacterial Vaginosis Drug Market, 2016-2028 (US$ Bn)
FIG. 26 Rest of Europe Bacterial Vaginosis Drug Market, 2016-2028 (US$ Bn)
FIG. 27 China Bacterial Vaginosis Drug Market, 2016-2028 (US$ Bn)
FIG. 28 Japan Bacterial Vaginosis Drug Market, 2016-2028 (US$ Bn)
FIG. 29 India Bacterial Vaginosis Drug Market, 2016-2028 (US$ Bn)
FIG. 30 South Korea Bacterial Vaginosis Drug Market, 2016-2028 (US$ Bn)
FIG. 31 Southeast Asia Bacterial Vaginosis Drug Market, 2016-2028 (US$ Bn)
FIG. 32 Rest of Asia Pacific Bacterial Vaginosis Drug Market, 2016-2028 (US$ Bn)
FIG. 33 Latin America Bacterial Vaginosis Drug Market, 2016-2028 (US$ Bn)
FIG. 34 Brazil Bacterial Vaginosis Drug Market, 2016-2028 (US$ Bn)
FIG. 35 Mexico Bacterial Vaginosis Drug Market, 2016-2028 (US$ Bn)
FIG. 36 Rest of Latin America Bacterial Vaginosis Drug Market, 2016-2028 (US$ Bn)
FIG. 37 Middle East & Africa Bacterial Vaginosis Drug Market, 2016-2028 (US$ Bn)
FIG. 38 GCC Countries Bacterial Vaginosis Drug Market, 2016-2028 (US$ Bn)
FIG. 39 South Africa Bacterial Vaginosis Drug Market, 2016-2028 (US$ Bn)
FIG. 40 Rest of Middle East and Africa Bacterial Vaginosis Drug Market, 2016-2028 (US$ Bn)

List of Tables

TABLE 1 Market Snapshot: Global Bacterial Vaginosis Drug Market
TABLE 2 Global Bacterial Vaginosis Drug Market, by Competitive Benchmarking, 2021
TABLE 3 Global Bacterial Vaginosis Drug Market, by Geographical Presence Analysis, 2021
TABLE 4 Global Bacterial Vaginosis Drug Market, by Key Strategies Analysis, 2021
TABLE 5 Global Bacterial Vaginosis Drug Market, by Type, 2016-2028 (US$ Bn)
TABLE 6 Global Bacterial Vaginosis Drug Market, by Application, 2016-2028 (US$ Bn)
TABLE 7 Global Bacterial Vaginosis Drug Market, by Geography, 2016-2028 (US$ Bn)
TABLE 8 North America Bacterial Vaginosis Drug Market, by Type, 2016-2028 (US$ Bn)
TABLE 9 North America Bacterial Vaginosis Drug Market, by Application, 2016-2028 (US$ Bn)
TABLE 10 North America Bacterial Vaginosis Drug Market, by Country, 2016-2028 (US$ Bn)
TABLE 11 US Bacterial Vaginosis Drug Market, by Type, 2016-2028 (US$ Bn)
TABLE 12 US Bacterial Vaginosis Drug Market, by Application, 2016-2028 (US$ Bn)
TABLE 13 Canada Bacterial Vaginosis Drug Market, by Type, 2016-2028 (US$ Bn)
TABLE 14 Canada Bacterial Vaginosis Drug Market, by Application, 2016-2028 (US$ Bn)
TABLE 15 Europe Bacterial Vaginosis Drug Market, by Type, 2016-2028 (US$ Bn)
TABLE 16 Europe Bacterial Vaginosis Drug Market, by Application, 2016-2028 (US$ Bn)
TABLE 17 Europe Bacterial Vaginosis Drug Market, by Country, 2016-2028 (US$ Bn)
TABLE 18 Germany Bacterial Vaginosis Drug Market, by Type, 2016-2028 (US$ Bn)
TABLE 19 Germany Bacterial Vaginosis Drug Market, by Application, 2016-2028 (US$ Bn)
TABLE 20 France Bacterial Vaginosis Drug Market, by Type, 2016-2028 (US$ Bn)
TABLE 21 France Bacterial Vaginosis Drug Market, by Application, 2016-2028 (US$ Bn)
TABLE 22 UK Bacterial Vaginosis Drug Market, by Type, 2016-2028 (US$ Bn)
TABLE 23 UK Bacterial Vaginosis Drug Market, by Application, 2016-2028 (US$ Bn)
TABLE 24 Italy Bacterial Vaginosis Drug Market, by Type, 2016-2028 (US$ Bn)
TABLE 25 Italy Bacterial Vaginosis Drug Market, by Application, 2016-2028 (US$ Bn)
TABLE 26 Spain Bacterial Vaginosis Drug Market, by Type, 2016-2028 (US$ Bn)
TABLE 27 Spain Bacterial Vaginosis Drug Market, by Application, 2016-2028 (US$ Bn)
TABLE 28 Rest of Europe Bacterial Vaginosis Drug Market, by Type, 2016-2028 (US$ Bn)
TABLE 29 Rest of Europe Bacterial Vaginosis Drug Market, by Application, 2016-2028 (US$ Bn)
TABLE 30 Asia Pacific Bacterial Vaginosis Drug Market, by Type, 2016-2028 (US$ Bn)
TABLE 31 Asia Pacific Bacterial Vaginosis Drug Market, by Application, 2016-2028 (US$ Bn)
TABLE 32 Asia Pacific Bacterial Vaginosis Drug Market, by Country, 2016-2028 (US$ Bn)
TABLE 33 China Bacterial Vaginosis Drug Market, by Type, 2016-2028 (US$ Bn)
TABLE 34 China Bacterial Vaginosis Drug Market, by Application, 2016-2028 (US$ Bn)
TABLE 35 Japan Bacterial Vaginosis Drug Market, by Type, 2016-2028 (US$ Bn)
TABLE 36 Japan Bacterial Vaginosis Drug Market, by Application, 2016-2028 (US$ Bn)
TABLE 37 India Bacterial Vaginosis Drug Market, by Type, 2016-2028 (US$ Bn)
TABLE 38 India Bacterial Vaginosis Drug Market, by Application, 2016-2028 (US$ Bn)
TABLE 39 South Korea Bacterial Vaginosis Drug Market, by Type, 2016-2028 (US$ Bn)
TABLE 40 South Korea Bacterial Vaginosis Drug Market, by Application, 2016-2028 (US$ Bn)
TABLE 41 South East Asia Bacterial Vaginosis Drug Market, by Type, 2016-2028 (US$ Bn)
TABLE 42 South East Asia Bacterial Vaginosis Drug Market, by Application, 2016-2028 (US$ Bn)
TABLE 43 Rest of Asia Pacific Bacterial Vaginosis Drug Market, by Type, 2016-2028 (US$ Bn)
TABLE 44 Rest of Asia Pacific Bacterial Vaginosis Drug Market, by Application, 2016-2028 (US$ Bn)
TABLE 45 Latin America Bacterial Vaginosis Drug Market, by Type, 2016-2028 (US$ Bn)
TABLE 46 Latin America Bacterial Vaginosis Drug Market, by Application, 2016-2028 (US$ Bn)
TABLE 47 Latin America Bacterial Vaginosis Drug Market, by Country, 2016-2028 (US$ Bn)
TABLE 48 Brazil Bacterial Vaginosis Drug Market, by Type, 2016-2028 (US$ Bn)
TABLE 49 Brazil Bacterial Vaginosis Drug Market, by Application, 2016-2028 (US$ Bn)
TABLE 50 Mexico Bacterial Vaginosis Drug Market, by Type, 2016-2028 (US$ Bn)
TABLE 51 Mexico Bacterial Vaginosis Drug Market, by Application, 2016-2028 (US$ Bn)
TABLE 52 Rest of Latin America Bacterial Vaginosis Drug Market, by Type, 2016-2028 (US$ Bn)
TABLE 53 Rest of Latin America Bacterial Vaginosis Drug Market, by Application, 2016-2028 (US$ Bn)
TABLE 54 Middle East and Africa Bacterial Vaginosis Drug Market, by Type, 2016-2028 (US$ Bn)
TABLE 55 Middle East and Africa Bacterial Vaginosis Drug Market, by Application, 2016-2028 (US$ Bn)
TABLE 56 GCC Countries Bacterial Vaginosis Drug Market, by Type, 2016-2028 (US$ Bn)
TABLE 57 GCC Countries Bacterial Vaginosis Drug Market, by Application, 2016-2028 (US$ Bn)
TABLE 58 South Africa Bacterial Vaginosis Drug Market, by Type, 2016-2028 (US$ Bn)
TABLE 59 South Africa Bacterial Vaginosis Drug Market, by Application, 2016-2028 (US$ Bn)
TABLE 60 Rest of Middle East and Africa Bacterial Vaginosis Drug Market, by Type, 2016-2028 (US$ Bn)
TABLE 61 Rest of Middle East and Africa Bacterial Vaginosis Drug Market, by Application, 2016-2028 (US$ Bn)

Frequently Asked Questions:

How does COVID-19 Impact the global bacterial vaginosis drug market?

The COVID-19 outbreak negatively impacted the market due to the transformation of the healthcare system to manage COVID-19 has resulted in medication launch cancellations and clinical trial delays.

Which is the leading region of the market for bacterial vaginosis drugs?

North America accounted for the major revenue share in the bacterial vaginosis drug market.

What are the key drivers for the growth of the bacterial vaginosis drug market?

The major drivers responsible for the market’s growth include the rising frequency of bacterial infections and vaginosis, increased research and development efforts, and awareness about women’s health.

Which is the major segment in the bacterial vaginosis drug market by type?

The Rx segment had a major share in the global market in 2021.

Which is the major segment in the bacterial vaginosis drug market by application?

The hospital segment had a major share in the global market.

Antineoplastic Agents Market

Published:
Report ID: 36065

US Retail Pharmacy Market

Published:
Report ID: 32801

OTC Vitamins Dietary Supplements Market

Published:
Report ID: 35994

Liposomes Market

Published:
Report ID: 35888

UK Iron Supplement Market

Published:
Report ID: 35709

U.S. Iron Supplement Market

Published:
Report ID: 35688

Malignant Ascites Market

Published:
Report ID: 11184

Middle East and Africa In-Vitro Fertilization (IVF) Market

Published:
Report ID: 35578

Chronic Myeloid Leukemia (CML) Treatment Market

Published:
Report ID: 2939

Combination Therapies In Aesthetics Market

Published:
Report ID: 35434

CAR T-Cell Therapy Market

Published:
Report ID: 2051

OTC Cough Cold And Allergy Medicine Market

Published:
Report ID: 20062

Purchase Options

$2999
Delivery Format: Excel.
$4999
Designed for the individual purchaser.
$6999
Users located at a single corporate site or regional office.
$7999
Allowed for unlimited sharing globally within one company.
Smallform of Sample request

Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –

Phone

+91 6232 49 3207


support

24/7 Research Support


sales@credenceresearch.com

– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN